Primary Sjogren Syndrome With Multisystem Involvement Clinical Trial
Official title:
Retrospective Study That Evaluate the Effect of HCG Treatment as a Cardiovascular Disease Morbidity Factor in Patients With Primary Sjogren Syndrome
sjogren syndrome is an autoimmune disease that mainly affects the Salivary glands and
Lacrimal gland In addition to the effects of this disease is characterized by overall
systemic Muskals injury, pulmonary disease, peripheral neuropathy and vasculitis. In
addition recent studies have shown that patients are at increased risk of the disease up to
2 cardiac events and stroke events Hydroxychloroquine is an RHEUMATIC DISEASE PROCESS
SUPPRESSANTS-ANTIMALARIALS used to treat anti-inflammatory rheumatic diseases in many
first-line treatment is sjogren syndrome.
A recent study of the treatment in Hydroxychloroquine effect on lipid profile sjogren
syndrome patients showed a reduction in total cholesterol levels and increase in HDL.
Further studies of the impact made Hydroxychloroquine systemic lupus patients erythematosus
(SLE) showed in Atherosclerosis and morbidity and mortality reduction in cardiovascular.
Studies of patients with rheumatoid arthritis (RA) demonstrated reduced risk of developing
diabetes and improved lipid profile Research Goals valuate The effect of HCQ treatment in
cardiovascular patients with primary sjogren syndrome
Research Goals Valuate The effect of HCQ treatment in cardiovascular patients with primary
sjogren syndrome Research Methods The study will included patients that diagnosed with
sjogren syndrome and was treated in Meir Medical center during the years 2003-2014 During
the study will collect information on confounding factors , Risk factors include
cardiovascular acceptable such as diabetes, dyslipidemia, high blood pressure and the like,
central nervous system involvement and steroid use
Study outcome will be one of the follow:
1. Thrombosis of peripheral veins
2. Arterial cardiovascular events
3. Cardiac events (myocardial infarction
4. Stroke (stroke and TIA)
4. Venous thrombosis events 5. Pulmonary embolism In the study will be 500 patients
Inclusion criteria:
1. 18 years old
2. Both sexes
3. Patients that diagnosis in sjogren in treated in Meir Medical center in the years
2003-2014 And treated in Hydroxychloroquine at least a month.
Exclusion criteria:
1. Minors and special populations
2. Patients that treated in Hydroxychloroquine at less than a month.
3. Patient that participate in clinical trial and treat with investigational product
;
Observational Model: Case-Only, Time Perspective: Retrospective